Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effect of Prophylactic Antipyretics on Immune Responses and Fever After 2014-2015 and 2015-2016 Inactivated Influenza Vaccine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02212990
Recruitment Status : Completed
First Posted : August 11, 2014
Last Update Posted : February 7, 2018
Sponsor:
Collaborator:
Centers for Disease Control and Prevention
Information provided by (Responsible Party):
Duke University

Brief Summary:

This study aims to conduct a double-blind, placebo-controlled study to assess the effect of prophylactic antipyretics on the immune responses and rates of fever after inactivated influenza vaccine (IIV) in children 6 through 47 months of age.

In this study, 160 healthy children, 6 through 47 months of age, including some children at risk of febrile seizure, will be randomized to one of three different treatment arms. Children will receive either blinded therapy with prophylactic acetaminophen or placebo immediately following and every 4 to 6 hours in the 24 hours after receipt of a dose of IIV or open-label ibuprofen every 6 to 8 hours in the 24 hours after receipt of a dose of IIV. Children will be followed for the occurrence of fever, fussiness, changes in appetite and sleep patterns, and use of medical services on the day of and for two days following vaccination. Antibody to influenza antigens contained in the respective 2014-2015 and 2015-2016 vaccines as measured by hemagglutination inhibition (HAI) antibody will be assessed at baseline and four weeks following vaccination. The proportions of children experiencing fever, having solicited side effects, using medical services, demonstrating a serologic response corresponding to seroprotection and seroconversion to each of the IIV antigens will be determined for groups of children in each of the three treatment arms. Likewise geometric mean HAI titers (GMTs) and corresponding 95% confidence intervals for each IIV antigen will be calculated for the three treatment arms. The investigators hope to learn whether or not prophylactic antipyretics affect the immune response and fever rates following IIV.


Condition or disease Intervention/treatment Phase
Fever Other: Acetaminophen Arm Other: Placebo Arm Other: Ibuprofen Arm Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 104 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Clinical Immunization Safety Assessment (CISA): A Study to Assess the Effect of Prophylactic Antipyretics on Immune Responses and Fever After 2014-2015 and 2015-2016 Inactivated Influenza Vaccine (IIV) Administered to Children 6 Through 47 Months of Age
Study Start Date : September 2014
Actual Primary Completion Date : March 2016
Actual Study Completion Date : March 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Fever Flu Flu Shot

Arm Intervention/treatment
Active Comparator: Acetaminophen Arm
Acetaminophen Suspension 160mg / 5mL Oral dose immediately following IIV and every 4 to 6 hours up to 24 hours (Maximum 5 oral doses)
Other: Acetaminophen Arm
Blinded Therapy

Placebo Comparator: Placebo Arm
Placebo Suspension Oral dose immediately following IIV and every 4 to 6 hours up to 24 hours (Maximum 5 oral doses)
Other: Placebo Arm
Blinded Therapy

Active Comparator: Ibuprofen Arm
Ibuprofen Suspension 100mg / 5mL Oral dose immediately following IIV and every 6 to 8 hours up to 24 hours (Maximum 4 oral doses)
Other: Ibuprofen Arm
Open Label Therapy




Primary Outcome Measures :
  1. Seroconversion [ Time Frame: One month following the last dose of IIV ]
    Seroconversion (an HAI titer ≥ 1:40 four weeks post- vaccination if the baseline titer is < 1:10 or a four-fold rise in HAI titer if the baseline titer is ≥ 1:10) for each IIV antigen


Secondary Outcome Measures :
  1. Seroprotection [ Time Frame: One month following the last dose of IIV ]
    Seroprotection (the proportion of subjects with an HAI titer >1:40) to each IIV antigen

  2. Geometric mean HAI titer [ Time Frame: One month following the last dose of IIV ]
    Geometric mean HAI titer (GMT) and 95% confidence interval for each IIV antigen


Other Outcome Measures:
  1. Fever [ Time Frame: Days 0, 1, and 2 following IIV ]
    Proportions of children with fever (≥ 38°C and ≥ 39°C) on days 0, 1, and 2 following IIV

  2. Systemic symptoms following IIV [ Time Frame: Days 0, 1, and 2 following IIV ]
    Proportions of children with fussiness, appetite change, or altered sleep on days 0, 1, and 2 following IIV

  3. Receipt of medical attention [ Time Frame: Days 0, 1, and 2 following IIV ]
    Proportions of children receiving medical attention on days 0, 1, and 2 following IIV



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   6 Months to 47 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. The child must be 6 through 47 months of age.
  2. The child must weigh 5.4 kilograms.
  3. The child must be receiving IIV this season.
  4. If the child is two years of age or older and needs two doses of influenza vaccine this season the parent/guardian intends for the child to receive IIV for the second dose.
  5. The parent/guardian must be willing and capable of providing written informed consent for the child.
  6. The parent/guardian must be available for follow-up and must at minimum have telephone access.
  7. The parent/guardian must agree to sign a medical release for the child so that study personnel may obtain medical information about the child's health (if needed).

Exclusion Criteria:

  1. History of receipt of current year's licensed influenza vaccine.
  2. Planned receipt of the live attenuated nasally administered influenza vaccine this year
  3. History of a severe allergic reaction (e.g. anaphylaxis) to any component of influenza vaccine, including egg protein, formaldehyde, octylphenol ethoxylate, gelatin, or thimerosal if using thimerosal containing vaccine.
  4. History of a severe allergic reaction (e.g. anaphylaxis) following a prior dose of influenza vaccine.
  5. History of an allergic reaction following acetaminophen or ingredients in the acetaminophen product.
  6. History of an allergic reaction following ibuprofen or ingredients in the ibuprofen product.
  7. History of an allergic reaction following aspirin or other pain reliever or fever reducer.
  8. History of liver disease.
  9. Currently taking the blood thinning drug warfarin (Coumadin) or other blood thinners.
  10. History of recent or planned heart surgery within the past 3 months or next 3 months.
  11. History of stomach ulcer or bleeding problem.
  12. Currently already routinely taking prescription or nonprescription non-steroidal anti-inflammatory drugs or NSAIDs (aspirin, ibuprofen, naproxen, or others)
  13. Received any other licensed vaccines within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to vaccination in this study or expects to receive a licensed vaccine during the 28 days following the last influenza vaccination in this study. Concomitant vaccinations are not allowed.
  14. Routine immunizations are delayed or will be delayed by not being able to receive a concomitantly administered vaccine or a needed vaccine in the 28 days following the last influenza vaccination in this study.
  15. Received an experimental/investigational agent (vaccine, drug, biologic, device, blood product, or medication) within 28 days prior to vaccination in this study, or expects to receive an experimental/investigational agent within the follow-up time period (28 days after the last vaccination in this study).
  16. A moderate to severe acute illness and/or a reported temperature greater than or equal to 100.0°F (37.8°C) within 72 hours prior to first dose of IIV or an axillary temperature greater than or equal to 100.0°F (37.8°C) at the time of enrollment. (This may result in a temporary delay of vaccination. For those needing a second dose of IIV, a moderate to severe acute illness and/or a reported temperature greater than or equal to 100.0°F (37.8°C) within 72 hours prior to second dose of IIV may result in a temporary delay of vaccination).
  17. Receipt of an antipyretic medication (acetaminophen or ibuprofen) within 72 hours prior to the first dose of IIV (This may result in a temporary delay of vaccination) or is already planning to administer a prophylactic antipyretic medication on the day of and the day following any dose of IIV (this exclusion does not apply if the caretaker indicates he/she might administer antipyretics after vaccination to reduce a fever).
  18. Immunosuppression as a result of an underlying illness or treatment, or use of anti-cancer chemotherapy or radiation therapy within the preceding 36 months.
  19. Long term (at least 14 days of prednisone 2 mg/kg/day or equivalent other glucocorticoid), any parenteral steroids, high-dose inhaled steroids (>800 mcg/day of beclomethasone dipropionate or equivalent) within the preceding 6 months (topical and nasal steroids are allowed).
  20. History of Guillain-Barré syndrome within 6 weeks of a prior dose of influenza vaccine.
  21. Has any condition that would, in the opinion of the site investigator, place the participant at an unacceptable risk of injury or render the participant unable to meet the requirements of the protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02212990


Locations
Layout table for location information
United States, North Carolina
Duke University Health System
Durham, North Carolina, United States, 27710
Sponsors and Collaborators
Duke University
Centers for Disease Control and Prevention
Investigators
Layout table for investigator information
Principal Investigator: Emmanuel B Walter, MD, MPH Duke Unviersity School of Medicine
Principal Investigator: Karen Broder, MD Centers for Diseaes Control and Prevention

Layout table for additonal information
Responsible Party: Duke University
ClinicalTrials.gov Identifier: NCT02212990     History of Changes
Other Study ID Numbers: Pro00056213
200-2012-53663 ( Other Grant/Funding Number: Centers for Disease Control and Prevention )
First Posted: August 11, 2014    Key Record Dates
Last Update Posted: February 7, 2018
Last Verified: April 2016

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Duke University:
Fever
Antipyretics
Acetaminophen
Ibuprofen
Influenza vaccine
Influenza
Body temperature changes
Signs and symptoms
Additional relevant MeSH terms:
Layout table for MeSH terms
Influenza, Human
Fever
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases
Body Temperature Changes
Signs and Symptoms
Acetaminophen
Ibuprofen
Vaccines
Antipyretics
Immunologic Factors
Physiological Effects of Drugs
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Anti-Inflammatory Agents, Non-Steroidal
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action